TRAMOMTANA (Multidisciplinary treatment of morbid obesity: Medication, behavioral therapy, nutritional support, and physical activity). From question to reality in an investigator-initiated clinical trial (II);TRAMOMTANA (Tratamiento Multidisciplinar de la Obesidad Mórbida: Medicamentos, Terapia de comportamiento, Apoyo Nutricional y Actividad física). De la pregunta a la realidad de un ensayo clínico investigador iniciado (II)

Endocrinologia y Nutricion

Volumn 58, Issue 6, 2011, Pages 299-307

  Tur, Juan ^a   Alòs, Maria ^a   Iglesias, Lourdes ^a   Luque, Lourdes ^a   Colom, Antoni ^a   Escudero, Antonio ^a   Martínez, David ^a   Pagán, Alberto ^a   Ugarriza, Elena ^a   Frontera, Marga ^a   Nicola, Gabriela ^a   Palomero, Antonio ^a   Tofé, Santiago ^a   Urgeles, Juan Ramón ^a   Barceló, María Antonia ^a   Couce, Marta ^a   De La Peña, Mónica ^a   Fiol, Miguel ^a   Cortés, Baltasar ^a   Terés, Emma ^a   Tumbarello, Ángela ^a   Álvarez, Cristina ^a   Salinas, Ramón ^a   Pereg, Vicente ^a   González, Xavier ^a   Burguera, Bartolomé ^a   more..

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Clinical trial; Health education; Interdisciplinarity; Morbid obesity; Research metodology; Weight loss program

Indexed keywords

ANTIOBESITY AGENT;

ARTICLE; BARIATRIC SURGERY; BEHAVIOR THERAPY; CLINICAL TRIAL (TOPIC); COMORBIDITY; GROUP THERAPY; HEALTH CARE COST; HEALTH CARE DELIVERY; LIFESTYLE MODIFICATION; MORBID OBESITY; NUTRITIONAL SUPPORT; PHYSICAL ACTIVITY; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; BARIATRIC SURGERY; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; DIET, REDUCING; EXERCISE THERAPY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICINE; MIDDLE AGED; NUTRITIONAL SUPPORT; OBESITY, MORBID; PATIENT CARE TEAM; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959709843     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2011.04.003     Document Type: Article

References (19)

1. Burguera B., Agusti A., Arner P., Baltasar A., Barbe F., Barcelo A., et al. Critical assessment of the current guidelines for the management and treatment of morbidly obese patients. International Symposium on Morbid Obesity. Morbid Obesity and its Comorbodities: an Interdisciplinary Approach. J Endocrinol Invest 2007, 30:844-852.
2. Flegal K.M., Carroll M.D., Ogden D.L., Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288:1723-1727.
3. Martinez J.A., Moreno B., Martinez-Gonzalez M.A. Prevalence of obesity in Spain. Obes Rev 2004, 3:171-172.
4. Conference: N.I.H. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991, 115:956-961.
5. Wadden T.A., Foster G.D. Behavioral treatment of obesity. Med Clin North Am 2000, 84:441-461.
6. Wing R.R., Blair E., Marcus M., Epstein L.H., Harvey J. Year-long weight loss treatment for obese patients with type 2 diabetes: does including an intermittent very-low-calorie diet improve outcome?. Am J Med 1994, 97:354-362.
7. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566-75.
8. Hofsø D., Nordstrand N., Johnson L.K., Karlsen T.I., Hager H., Jenssen T., et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 2010, 163:735-745.
9. Van Baak M.A., van Mil E., Astrup A.V., Finer N., Van Gaal L.F., Hilsted J., et al. Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). Am J Clin Nutr 2003, 78:209-214. STORM Study Group.
10. Arterburn D.E., Crane P.K., Veenstra D.L. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004, 164:994-1003.
11. Torgerson J.S., Hauptman J., Boldrin M.N., Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161.
12. Muls E., Kolanowski J., Scheen A., Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001, 25:1713-1721. ObelHyx Study Group.
13. Kaya A., Aydin N., Topsever P., Filiz M., Oztürk A., Daĝar A., et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004, 58:582-587.
14. Wadden T.A., Berkowitz R.I., Sarwer D.B., Prus-Wisniewski R., Steinberg C. Randomized trial of lifestyle modification in the pharmacologic treatment of obesity. N Engl J Med 2005, 353:2111-2120.
15. Sjostrom L., Narbro K., Sjostrom C.D., Karason K., Larsson B., Wedel H., et al. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects. NEJM 2007, 357:741-752. the Swedish Obese Subjects Study.
16. Pories W.J., et al. Who would have thought it ? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995, 222:339-350. discussion 350-352.
17. Schauer P.R., Ikramuddin S., Gourash W., Ramanathan R., Luketich J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000, 232:515-529.
18. Scopinaro N., Marinari G.M., Camerini G.B., Papadia F.S., Adami G.F. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005, 28:2406-2411.
19. Schauer P.R., Burguera B., Ikramuddin S., Cottam D., Gourash W., Hamad G., et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003, 238:467-484.